Finance

Lists
DSKYF:OTCMKTS
Daiichi Sankyo Co Ltd
16,04 US$
+1,07%
(+0,17) 1D
13 ოქტ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DSKYF...
Open
15,51 US$
High
16,04 US$
Low
15,51 US$
Mkt. cap
30,73 მლრდ.
Avg. vol.
2,71 ათ.
Volume
24,35 ათ.
52-wk high
29,10 US$
52-wk low
13,85 US$
Beta
-1,13
Shares outstanding
1,86 მლრდ.
No. of employees
20 ათ.
Open
15,51 US$
High
16,04 US$
Low
15,51 US$
Mkt. cap
30,73 მლრდ.
Avg. vol.
2,71 ათ.
Volume
24,35 ათ.
52-wk high
29,10 US$
52-wk low
13,85 US$
Beta
-1,13
Shares outstanding
1,86 მლრდ.
No. of employees
20 ათ.
News stories
From web sources and news partners
Profile
Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 1,278 billion in revenue in 2022. The company owns the American pharmaceutical company American Regent. Daiichi Sankyo, Inc. began operating in the U.S. in 2006. It is the U.S. subsidiary of Daiichi Sankyo Company, Limited, and a member of the Daiichi Sankyo Group. The organization, which includes U.S. commercial operations and global clinical development, is headquartered in Basking Ridge, New Jersey. Daiichi Sankyo Europe, GmbH, the European subsidiary, is headquartered in Munich, Germany. The organization is responsible for development and manufacturing for 12 European countries. Daiichi Sankyo Company, Limited is a full member of the European Federation of Pharmaceutical Industries and Associations and of the International Federation of Pharmaceutical Manufacturers and Associations. Wikipedia
About Daiichi Sankyo Co Ltd
CEOჰიროიოკი ოკუზავა
Employees20,2 ათ.
Founded28 სექ. 2005
Headquartersჩუო, ტოკიო, იაპონია
Sector-
Previous reportsAll values in JPY
Loading Previous Earnings...
Revenue
Net income
All values in JPY
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
500,76 მლრ.
558,11 მლრ.
589,59 მლრ.
574,74 მლრ.
Cost of goods sold
155,98 მლრ.
118,28 მლრ.
302,44 მლრ.
124,29 მლრ.
Cost of revenue
155,98 მლრ.
118,28 მლრ.
302,44 მლრ.
124,29 მლრ.
Research and development expenses
111,72 მლრ.
122,11 მლრ.
126,23 მლრ.
115,46 მლრ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
189,08 მლრ.
228,23 მლრ.
154,06 მლრ.
249,96 მლრ.
Operating expense
297,25 მლრ.
350,29 მლრ.
279,38 მლრ.
365,35 მლრ.
Total operating expenses
453,23 მლრ.
468,57 მლრ.
581,82 მლრ.
489,64 მლრ.
Operating income
47,52 მლრდ.
89,54 მლრდ.
7,77 მლრდ.
85,10 მლრდ.
Other non operating income
-
-
6,22 მლრდ.
-2,00 მლნ.
EBT including unusual items
57,78 მლრდ.
106,73 მლრ.
22,44 მლრდ.
91,34 მლრდ.
EBT excluding unusual items
57,78 მლრდ.
106,73 მლრ.
7,84 მლრდ.
91,34 მლრდ.
Income tax expense
12,46 მლრდ.
20,10 მლრდ.
-39,84 მლრდ.
22,70 მლრდ.
Effective tax rate
21,57%
18,83%
-177,52%
24,86%
Other operating expenses
-3,56 მლრდ.
-49,00 მლნ.
-908,00 მლნ.
-69,00 მლნ.
Net income
45,31 მლრდ.
86,63 მლრდ.
62,28 მლრდ.
68,64 მლრდ.
Net profit margin
9,05%
15,52%
10,56%
11,94%
Earnings per share
-
-
-
-
Interest and investment income
10,68 მლრდ.
19,08 მლრდ.
377,00 მლნ.
9,74 მლრდ.
Interest expense
-834,00 მლნ.
-2,16 მლრდ.
-18,91 მლრდ.
-3,23 მლრდ.
Net interest expenses
9,84 მლრდ.
16,91 მლრდ.
-18,53 მლრდ.
6,51 მლრდ.
Depreciation and amortization charges
-
-
-
-
EBITDA
66,41 მლრდ.
109,18 მლრ.
28,89 მლრდ.
106,58 მლრ.
Gain or loss from assets sale
1,75 მლრდ.
573,00 მლნ.
8,50 მლრდ.
180,00 მლნ.
AI content may include mistakes. Learn more
Google აპები